Skip to main content
Evidence Snapshot

Histone deacetylase 3

CHEMBL1829 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1829
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone deacetylase 3 as ChEMBL target CHEMBL1829, mapped to UniProt O15379. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histone deacetylase 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1829
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O15379
Histone deacetylase 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Histone deacetylase 3 matters

As of 2026-09-13

Histone deacetylase 3 is reviewed as Histone deacetylase 3 (UniProt O15379); Histone deacetylase 3 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 11 approved drugs, 3447 compounds, and 762 assays, with lead potency reaching pChEMBL 10.4.

Disease context
cancer

Histone deacetylase 3 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include MOCETINOSTAT, VORINOSTAT.

Start review with cancer because it currently carries approved-linked support. Linked drugs include MOCETINOSTAT, VORINOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 3447 compounds, and 762 assays for this target. The dominant activity type is IC50. CHEMBL5413269 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL5413269 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Histone deacetylase 3 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O15379, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3447
Total Compounds
762
Total Assays
11
Approved Drugs
IC50: 3894.0, KI: 114.0, EC50: 2.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5413269
 10.4 Ki —
No preferred name
CHEMBL4860000
 10.2 IC50 —
No preferred name
CHEMBL4862152
 10.1 IC50 —
No preferred name
CHEMBL4641682
 10.1 IC50 —
No preferred name
CHEMBL4649205
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
GIVINOSTAT
CHEMBL1213492
 2024
PANOBINOSTAT
CHEMBL483254
 2015
BELINOSTAT
CHEMBL408513
 2014
ROMIDEPSIN
CHEMBL343448
 2009
BENDAMUSTINE
CHEMBL487253
 2008
VORINOSTAT
CHEMBL98
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:09:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1829